Some of the losses are down to pharma's broader problems: notably, President Trump's tariff and price-cut threats. But there ...

The drug, which is estimated to be taken by up to 750,000 people, is one of the country's most popular weight loss and ...

The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 billion. The midpoint suggests a 35% increase in sales for the full year.